This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

PraevoSkin Emulsion in the Prevention of Radiation Induced Dermatitis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2009 by Pharm Olam Pharmaceuticals Ltd..
Recruitment status was:  Active, not recruiting
Information provided by:
Pharm Olam Pharmaceuticals Ltd. Identifier:
First received: February 7, 2009
Last updated: May 5, 2009
Last verified: May 2009
A phase 2 double blind randomised study of PraevoSkin,a melatonin containing emulsion, in the prevention of radiation induced dermatitis.

Condition Phase
Prevention of Radiation Induced Dermatitis. Phase 2

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: A Phase 2,Double Blind Randomized Study of PraevoSkin,a Melatonin Containing Emulsion, in the Prevention of Radiation Induced Dermatitis.

Further study details as provided by Pharm Olam Pharmaceuticals Ltd.:

Primary Outcome Measures:
  • Digital Camera [ Time Frame: Weekly ]

Estimated Enrollment: 1
Study Start Date: February 2009
Estimated Study Completion Date: August 2009
Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Female patientsplanned to receive whole breast radiation.

Inclusion Criteria:

  1. Female patients at least 18 years with unilateral breast cancer following lumpectomy +/- chemotherapy.
  2. Planned to receive 50 Gy whole breast irradiation +/- boost to tumor bed.
  4. Capable of giving written informed consent and following instructions for applying study emulsion or placebo as per control.
  5. No co-morbidities known to affect radiotherapy reactions.
  6. No co-existing acute or chronic skin disease.
  7. No evidence of infection or inflammation of breast to be treated.
  8. Not receiving chemotherapy during radiotherapy course.Biological therapy (e.g. Herceptin) or hormone therapy will be allowed during the study.

Exclusion Criteria:

  1. Chemotherapy within 4 weeks prior to planned start of radiation or chemotherapy planned during radiation.
  2. Prior radiotherapy to any site.
  3. Collagen vascular disease.
  4. Diabetes mellitus requiring medication.
  5. Uncontrolled hypertension.
  6. Participation in other clinical study.
  7. Any contra-indicating to treatment with Melatonin.
  8. History of allergy to peanuts or fragrances.
  9. History of severe allergic reactions (e.g. asthma).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Roni Eilon, Pharm Olam Pharmaceutics Ltd. Identifier: NCT00840515     History of Changes
Other Study ID Numbers: SMC-5467
Study First Received: February 7, 2009
Last Updated: May 5, 2009

Additional relevant MeSH terms:
Skin Diseases
Radiation Injuries
Wounds and Injuries processed this record on September 21, 2017